Manufacturers/Gilead Sciences, Inc.

Gilead Sciences, Inc.

18 drugs in NADAC|0 Generic,18 Brand

View Recalls (7)

Gilead Sciences, Inc. lists 18 NDCs in the CMS NADAC file (0 generic, 18 brand), at an average NADAC of $285.92 per unit, with a week-over-week move of -0.0% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.

Total Drugs

18

0G / 18B

Avg Price / Unit

$285.9225

$17.45 – $1098.94

Avg 7d Change

-0.01%

Across 8 drugs with changes

7d Activity

5310 flat

of 18 total drugs

Portfolio Price Trend

Monthly average NADAC price across all drugs

Frequently Asked Questions

How many drugs does Gilead Sciences, Inc. make?

Gilead Sciences, Inc. lists 18 NDCs in the CMS NADAC file — 0 generic and 18 brand products.

What is the average price of Gilead Sciences, Inc. drugs?

The average NADAC across Gilead Sciences, Inc.'s portfolio is $285.9225 per unit, ranging from $17.4459 to $1098.9375.

What types of drugs does Gilead Sciences, Inc. make?

Gilead Sciences, Inc. makes drugs across 8 FDA pharmacologic classes. The most common by NDC count are Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor (25), Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor (13), Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor (4), Hepatitis C Virus NS5A Inhibitor (3), Cytochrome P450 3A Inhibitor (2).

Has Gilead Sciences, Inc. had any drug recalls?

7 FDA recalls are matched to Gilead Sciences, Inc. in the openFDA feed, most recently on Sep 19, 2024.

How has Gilead Sciences, Inc.'s pricing changed recently?

Over the past 7 days, 5 Gilead Sciences, Inc. products rose and 3 fell, with a portfolio-wide average change of -0.0%.

Drug Portfolio

18 drugs total, 18 shown

Drug Price 7d Change
HARVONI 90-400 MG TABLET
LEDIPASVIR and SOFOSBUVIR
$1098.9375
per EA
SOVALDI 400 MG TABLET
SOFOSBUVIR
$975.3000
per EA
EPCLUSA 400 MG-100 MG TABLET
Velpatasvir and Sofosbuvir
$865.9619
per EA
VOSEVI 400-100-100 MG TABLET
SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR
$858.6884
per EA
STRIBILD TABLET
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
$149.6307
per EA
-0.25%
GENVOYA TABLET
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
$143.3497
per EA
+0.01%
BIKTARVY 50-200-25 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
$136.7401
per EA
0.00%
BIKTARVY 50-200-25 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
$136.7401
per EA
0.00%
BIKTARVY 30-120-15 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
$136.6695
per EA
-0.02%
ODEFSEY TABLET
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
$130.3845
per EA
+0.03%
COMPLERA TABLET
emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
$130.1411
per EA
+0.09%
DESCOVY 200-25 MG TABLET
emtricitabine and tenofovir alafenamide
$71.4409
per EA
0.00%
DESCOVY 200-25 MG TABLET
emtricitabine and tenofovir alafenamide
$71.4409
per EA
0.00%
DESCOVY 120-15 MG TABLET
emtricitabine and tenofovir alafenamide
$71.3575
per EA
TRUVADA 200 MG-300 MG TABLET
emtricitabine and tenofovir disoproxil fumarate
$59.7039
per EA
-0.03%
VEMLIDY 25 MG TABLET
tenofovir alafenamide
$51.9421
per EA
+0.03%
VIREAD 300 MG TABLET
TENOFOVIR DISOPROXIL FUMARATE
$40.7299
per EA
0.00%
EMTRIVA 200 MG CAPSULE
EMTRICITABINE
$17.4459
per EA
+0.05%

FDA Recalls (7)

Recalls matched by company name. Verify current status with FDA.

D-0005-2025
Terminated
Class I

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Presence of Particulate Matter: Presence of glass particle.

Initiated: 9/19/2024
D-0299-2022
Terminated
Class I

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

Initiated: 12/3/2021
D-0045-2015
Terminated
Class II

Emtriva (emtricitabine) Oral Solution, 10 mg/mL, 170 mL bottles, Rx only, Manufactured for Gilead Sciences, Inc., Foster City, CA NDC 61958-0602-1 Gilead Sciences, Inc. Foster City, CA 94404.

Defective Container; leaking around the cap

Initiated: 10/1/2014
D-0013-2015
Terminated
Class III

Truvada (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablets, 30 count bottles, Rx only, Manufactured for Gilead Sciences, Inc. Foster City, CA 94404, NDC 61958-0701-1

Presence of Foreign Substance: Truvada was found to contain small red silicone rubber particulates.

Initiated: 9/30/2014
D-1090-2014
Terminated
Class III

Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets, 30 Tablet Bottles, Rx only. Manufactured for: Bristol-Myers Squibb & Gilead Sciences, LLC, Foster City, CA 94404. Made in Ireland. NDC 15584-0101-1. Manufactured for: Bristol-Myers-Squibb & Gilead Sciences, LLC, Foster City, CA 94404 Made in Ireland

Presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.

Initiated: 2/19/2014
D-821-2013
Terminated
Class II

AmBisome (amphotericin B) liposome for Injection, 50 mg, For Intravenous Infusion Only, Single-Use Vial, Rx Only, Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062, Manufactured by: Gilead Sciences, Inc., San Dimas, CA 91773, NDC 0469-3051-30.

Lack of Sterility Assurance; During a routine simulation of the manufacturing of AmBisome, a bacterial contamination was detected in some media fill units. No contaminated batches have actually been identified in the finished product, but there is a possibility of contamination.

Initiated: 6/20/2013
D-324-2013
Terminated
Class I

Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.

Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).

Initiated: 1/31/2013